The antiresorptive effects of a single dose of zoledronate persist for two years: A randomized, placebo-controlled trial in osteopenic postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 538-544

  Grey, Andrew ^a   Bolland, Mark J ^a   Wattie, Diana ^a   Horne, Anne ^a   Gamble, Greg ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EYE INFLAMMATION; FEMALE; FIBULA FRACTURE; FOREARM FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; METACARPAL BONE FRACTURE; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 59749087104     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2241     Document Type: Article

References (19)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
2. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
3. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
4. Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P 2007 Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211-1218
5. Bolland M, Grey A, Horne A, Briggs S, Thomas M, Ellis-Pegler R, Callon K, Gamble G, Reid I 2008 Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 23:1304-1308
6. Thiébaud D, Husi B, Jacquet AF, Burckhardt P 1997 Effects of ibandronate i.v. bolus injection in healthy men and postmenopausal women. J Bone Miner Res 12(Suppl 1):S343
7. O'Brien PC, Fleming TR 1979 A multiple testing procedure for clinical trials. Biometrics 39:549-556
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 3rd CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
9. Borba VZ, Paz-Filho G, Kulak CA, Seibel MJ, Bilezikian JP 2007 Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract 61:1058-1062
10. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE 2007 Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406-5410
11. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
12. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
13. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625
14. Recker RR, Weinstein RS, Chesnut CH, Schimmer RC, Mahoney P, Hughes C, Bonvoisin B, Meunier PJ 2004 Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231-237
15. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW 2007 Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40:391-398
16. Kim CH, Takai E, Zhou H, von Stechow D, Muller R, Dempster DW, Guo XE 2003 Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116-2125
17. Rubin MR, Cosman F, Lindsay R, Bilezikian JP 2002 The anabolic effects of parathyroid hormone. Osteoporos Int 13:267-277
18. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
19. Cramer J, Gold D, Silverman S, Lewiecki E 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031